Use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) post-endovascular thrombectomy in diabetic patients is associated with significantly better 3-month functional outcomes.
The study demonstrates improved distribution in modified Rankin Scale scores and higher odds of favorable and excellent 3-month recovery.
Consistent results across multiple propensity score analyses from a large multicenter cohort reinforce the robustness of the findings.
This evidence supports further prospective trials to clarify the therapeutic role of SGLT2i in poststroke diabetes management.
